| Alexion: One-Trick Pony, But It's a Pretty Good Trick Jason Chew submits: Alexion (ALXN) got some good news yesterday, receiving earlier than expected approval for its drug, Soliris (eculizumab), for the treatment of PNH in Japan - the world’s second largest pharmaceuticals market. Having received approval from the FDA and the European Commission only in 2007, Soliris has rocketed to expected 2010 sales of over $500 Million. Alexion has been profitable since the second quarter 2008; that speaks highly to a disciplined management team and quality of Alexion’s sales efforts.What is Soliris?Complete Story » seekingalpha.com |
Genoptix Reports Operating Results for the Second Quarter 2010 (PR Newswire) Genoptix, Inc. , a specialized laboratory services provider, today reported revenue of $50.9 million for the second quarter of 2010.  Net income was $5.6 million or $0.31 per diluted share for the quarter. us.rd.yahoo.com |
Cord Blood America Inc. is Today's Focus Stock on MicroStockProfit.com (GlobeNewswire) DALLAS -- MicroStockProfit.com announces an investment report featuring Cord Blood America Inc. . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. us.rd.yahoo.com |
Pfizer Is Not Paying a Ransom for King EP Vantage submits:Considering King Pharmaceuticals' (KG) share price has not been anywhere close to $14.25 in the last three years, Pfizer’s (PFE) takeover offer will look pretty tempting to a lot of the company’s shareholders. The bid announced Tuesday morning values King at $3.6bn, 40% more than the pain specialist’s market value Monday. The move makes sense given Pfizer’s significant presence in CNS, led by blockbusters Lyrica and Celebrex, but less so when considering King’s far from spotless progress over the last 18 months in getting new products to market. A move typical for a company that cannot help itself when it comes to acquisitions, perhaps, but hardly one that will lessen the Lipitor patent cliff. Complete Story » seekingalpha.com |
LabCorp is Scheduled to Present at the 22nd Annual Piper Jaffray Health Care Conference [Business Wire] - Laboratory Corporation of America® Holdings today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 22nd Annual Piper Jaffray Health Care Conference in New York City, NY. us.rd.yahoo.com |